The Cure Sickle Cell Initiative: Catalyzing Progress via Innovative Interfaces Between NIH, Patients, Academics, ASH, and the Private Sector
Dr. Edward Benz provides some background on the discovery of sickle cell disease and development of the Cure Sickle Cell Initiative. Dr. Ify Osunkwo adds further perspectiv
A New Standard of Care for Children and Young Adults With T-cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that shows outstanding outcomes for children and young adults with T-cell acute lymphoblastic leukemia that have raised the bar and established
Drs. Mehdi Hamadani, Mikkael Sekeres, and Martha Sola-Visner talk about exciting sessions and features available at the 60th ASH Annual Meeting in San Diego.
Dr. Parameswaran Hari discusses Sapiens, a compelling story of our species he believes every human could benefit from reading.
Dr. David Sallman sheds light on the profound negative connotation of TP53 mutation in myelodysplastic syndromes and the immediate need for effective biologically rational, targeted therapies.
November/December 2018Volume 15, Issue 6
View all Features articles
View all Diffusion articles
In her final President's Column, Dr. Thompson looks back at a year full of change and advancement, and provides a glimpse of what's to come in 2019 and beyond for ASH.
View all president's column articles
View all Ask the Hematologist articles
View all Clinical Trials Corner articles
View all Mini Review articles
2018 was full of federal policies and proposals related to
access to care and drug pricing. The Administration made more changes to the
Affordable Care Act and highlighted that drug pricing is a priority.
CMS released a National Coverage Determination entitled Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer. ASH submitted comments on the proposal along with over 300 other groups, including physician specialty societies, patient advocacy groups, and industry groups.
Senators Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018.
On December 20, the House of Representatives and the Senate voted to approve H.R. 1, tax reform legislation. Select members of each chamber came together to resolve disagreements between the two versions passed by the House and Senate.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology